Spero Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Spero Therapeutics generated cash of -$32,994,999, which is less than the previous year. Cash used in financing activities reached the amount of $221,000 last year. Net change in cash is therefore -$32,774,000.
Cash Flow
| 2015 | -9.60M | -232K | 15.27M |
|---|---|---|---|
| 2016 | -28.95M | -830K | 34.41M |
| 2017 | -39.11M | -27K | 116.11M |
| 2018 | -39.62M | -83.15M | 69.52M |
| 2019 | -50.02M | 29.53M | 16.14M |
| 2020 | -85.87M | 10.47M | 130.88M |
| 2021 | -64.34M | 7.67M | 84.05M |
| 2022 | -7.73M | 33.80M | -29.55M |
| 2023 | -32.99M | 0 | 221K |
SPRO Cash Flow Statement (2015 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 109.10M | 112.58M | 85.20M | 29.73M | 34.08M | 87.33M | 10.31M | 5.69M | 256K |
Operating activities | |||||||||
Net income | 22.80M | -46.41M | -89.75M | -78.28M | -60.92M | -41.66M | -39.88M | -32.64M | -13.15M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 367K | 869K | 646K | 761K | 750K | 409K | 363K | 279K | 11K |
Stock-based compensation expense | 7.93M | 9.12M | 9.43M | 4.88M | 3.77M | 0 | 1.42M | 180K | 21K |
| Deferred income tax benefit | 7.93M | 9.12M | 9.43M | 4.88M | 3.77M | 0 | 1.42M | 180K | 21K |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | 0 | 1.54M | 3.83M | 2.17M | -7.08M | 1.40M | -2.51M | -294K | -10K |
Inventories | 0 | -1.54M | -3.83M | -2.17M | 7.08M | 0 | 0 | 0 | 0 |
Accounts payable | 761K | -484K | -53K | -2.97M | 564K | 84K | 2.34M | -644K | 671K |
Cash generated by operating activities | -32.99M | -7.73M | -64.34M | -85.87M | -50.02M | -39.62M | -39.11M | -28.95M | -9.60M |
Investing activities | |||||||||
Purchases Of Investments | 0 | -26.97M | -43.91M | -45.72M | -88.99M | -130.17M | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | 39K | -157K | -314K | -2.43M | -27K | -830K | -232K |
Acquisitions Net | 0 | 0 | -39K | -10.62M | -29.84M | 83.15M | -1.17M | 0 | 0 |
Cash generated by investing activities | 0 | 33.80M | 7.67M | 10.47M | 29.53M | -83.15M | -27K | -830K | -232K |
Financing activities | |||||||||
Common Stock Issued | 221K | 24.51M | 36.57M | 78.66M | 15.79M | 70.5M | 77.74M | 34.41M | 15.30M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -47.48M | -333K | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 221K | -29.55M | 84.05M | 130.88M | 16.14M | 69.52M | 116.11M | 34.41M | 15.27M |
Net Change In Cash | -32.77M | -3.47M | 27.37M | 55.47M | -4.35M | -53.25M | 76.97M | 4.62M | 5.43M |
Cash at end of period | 76.33M | 109.10M | 112.58M | 85.20M | 29.73M | 34.08M | 87.28M | 10.31M | 5.69M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |